Abstract
The biological age of the brain differs from its chronological age (CA) and can be used as biomarker of neural/cognitive disease processes and as predictor of mortality. Brain age (BA) is often estimated from magnetic resonance images (MRIs) using machine learning (ML) that rarely indicates how regional brain features contribute to BA. Leveraging an aggregate training sample of 3 418 healthy controls (HCs), we describe a ridge regression model that quantifies each region’s contribution to BA. After model testing on an independent sample of 651 HCs, we compute the coefficient of partial determination R̄2 p for each regional brain volume to quantify its contribution to BA. Model performance is also evaluated using the correlation r between chronological and biological ages, the mean absolute error (MAE ) and mean squared error (MSE) of BA estimates. On training data, r = 0.92, MSE = 70.94 years, MAE = 6.57 years, and R̄2 = 0.81; on test data, r = 0.90, MSE = 81.96 years, MAE = 7.00 years, and R̄2 = 0.79. The regions whose volumes contribute most to BA are the nucleus accumbens (R̄2 p = 7.27%), inferior temporal gyrus (R̄2 p = 4.03%), thalamus (R̄2 p = 3.61%), brainstem (R̄2 p = 3.29%), posterior lateral sulcus (R̄2 p = 3.22%), caudate nucleus (R̄2 p = 3.05%), orbital gyrus (R̄2 p = 2.96%), and precentral gyrus (R̄2 p = 2.80%). Our ridge regression, although outperformed by the most sophisticated ML approaches, identifies the importance and relative contribution of each brain structure to overall BA. Aside from its interpretability and quasi-mechanistic insights, our model can be used to validate future ML approaches for BA estimation.
| Original language | English |
|---|---|
| Pages (from-to) | 872-881 |
| Number of pages | 10 |
| Journal | Journals of Gerontology - Series A Biological Sciences and Medical Sciences |
| Volume | 78 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2023 |
Bibliographical note
Publisher Copyright:© The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America.
Funding
This work was supported by the National Institutes of Health grant R01 NS 100973 to A.I., by the US Department of Defense contract W81XWH-18-1-0413 to A.I., by a Hanson-Thorell Family Research Scholarship, and by the James J. and Sue Femino Foundation. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The ADNI grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data for this study were provided, in part, by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research and by the McDonnell Center for Systems Neuroscience at Washington University. Research reported in this publication was also supported by the National Institute on Aging of the National Institutes of Health under Award Number U01 AG 052564. Cam-CAN funding was provided by the UK Biotechnology and Biological Sciences Research Council (grant number BB/H008217/1), together with support from the UK Medical Research Council and University of Cambridge, UK. The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or of the University of Southern California. The funding sources had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.
| Funders | Funder number |
|---|---|
| Northern California Institute for Research and Education | |
| UK Medical Research Council, Engineering and Physical Sciences Research Council | |
| James J. and Sue Femino Foundation | |
| National Institute of Biomedical Imaging and Bioengineering | |
| Cambridge University | |
| DOD ADNI | |
| National Institute on Aging | |
| DoD Alzheimer's Disease Neuroimaging Initiative | U01 AG024904 |
| National Institutes of Health (NIH) | R01 NS 100973 |
| U.S. Department of Defense | W81XWH-12-2-0012, W81XWH-18-1-0413 |
| Biotechnology and Biological Sciences Research Council | BB/H008217/1 |
| University of Southern California | 1U54MH091657 |
| McDonnell Center for Systems Neuroscience | U01 AG 052564 |
Keywords
- Brain aging
- Cognitive decline
- Human aging
- Imaging
ASJC Scopus subject areas
- Aging
- Geriatrics and Gerontology